SMi's 6th Annual Biomarkers Summit - Innovations In Stratified Medicine, 16-17 January 2013, London

Date: Oct-03-2012The drive towards personalized medicine is seeing pharma move from patient stratification as a 'nice to have', to an essential feature of product development. Exemplified by the success of Herceptin, biomarkers promise to transform drug discovery, clinical development and diagnostics in the R&D process. This dynamic market, poised to reach a value of $33.3 billion by 2015, will continue to improve decision-making, clinical trial success rates and translational productivity.

Drawing on advances in genomics, translational medicine and clinical trial design, SMi's sixth annual Biomarkers Summit held on 16th &17th January 2013 London brings you the latest developments from toxicity testing to compound screening and first-in-man studies to companion diagnostic assays, stay competitive with fresh insights from companies at the cutting edge of biopharmaceutical development. Attending will enable you to:
Accelerate companion diagnostics development for therapeutic indications

Validate and deliver biomarkers for patient selection during clinical trials

Implement sub-grouping in patient segmentation studies

Utilise revised FDA regulatory guidelines to aid product development

Optimise reimbursement strategies for diagnostics

Maximise biomarker identification using epigenetic and metabolomic insights

For more information visit http://www.smi-online.co.uk/goto/biomarkers-summit19.asp alternatively contact Farhaana Rahman on +44 0 207 827 6186 or email on frahman@smi-online.co.uk

View drug information on Herceptin.
Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.